Merck is pleased to announce that EMEND for oral suspension is now available.

Merck is pleased to announce that EMEND for oral suspension is now available.

(Click the below image to enlarge)

Emend Announcement

 

 

EMEND® is a substance P/neurokinin 1 (NK1) receptor antagonist.

EMEND for oral suspension is indicated in combination with other antiemetic agents, in patients 6 months of age and older for prevention of:

  • acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin (1.1)
  • nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)

Prescribing Information<http://www.merck.com/product/usa/pi_circulars/e/emend/emend_pi.pdf>

Patient Information<http://www.merck.com/product/usa/pi_circulars/e/emend/emend_ppi.pdf>

Instructions for Use<http://www.merck.com/product/usa/pi_circulars/e/emend/emend_ifu.pdf>

 

© 2021 FLASCO | Premium Website Design by The HDG

FLASCO